Alzheimer's Disease Education and Referral Center

Pomegranate Extract and Memory

Pomegranate Extract and Memory

Overall Status: 
Active, not recruiting
Brief Description: 

This study will examine whether pomegranate extract benefits cognitive abilities in middle-aged and older people without dementia. Investigators expect that participants who take pomegranate extract supplement will show better cognitive performance than those who receive a placebo, though response will vary according to a genetic risk for Alzheimer's.

Patient Qualifications: 
Min AgeMax AgeGenderHealthy Volunteers
50 Years
75 Years
Both
Accepts Healthy Volunteers
Inclusion Criteria: 
    • Normal cognition or mild cognitive impairment
    • Adequate seeing and hearing ability to allow neuropsychological testing
    • Normal results for screening laboratory tests and EKG; if results are abnormal, participant must obtain primary care physician's written clearance
Exclusion Criteria: 
    • Diagnosis of probable Alzheimer's disease or other dementia such as vascular, Lewy body, or frontotemporal
    • Evidence of other neurological or physical illness that can produce cognitive deterioration
    • Significant cerebrovascular disease, myocardial infarction within the previous year, unstable cardiac disease, or uncontrolled hypertension (systolic blood pressure over 170 mmHg or diastolic blood pressure over 100 mmHg)
    • History of stroke, transient ischemic attack, carotid bruits, or lacunes seen on MRI scans
    • Contraindication to MRI, including claustrophobia, metal in body, surgery within 60 days, certain implants or previous abnormal MRI results
    • Evidence of Parkinson's disease
    • History of significant liver disease, clinically significant pulmonary disease, or diabetes
    • Current diagnosis of any major psychiatric disorder, current or past alcoholism or substance addiction
    • Regular use of any medication that may affect cognitive functioning: centrally active beta-blockers, narcotics, clonidine, antiparkinsonian medications, antipsychotics, systemic corticosteroids, medications with significant cholinergic or anticholinergic effects, anticonvulsants, or warfarin
    • Occasional use of anxiety or sleeping medications known to cause cognitive dulling will be allowed but discouraged: chloral hydrate, nonbenzodiazepine hypnotics such as zolpidem (Ambien®), eszopiclone (Lunesta®), and benzodiazepines such as lorazepam (Ativan®), alprazolam (Xanax®), clonazepam (Klonopin®), and temazepam (Restoril®)
    • Prohibited medications: amitriptyline, amiodarone, desipramine, fenofibrate, flecainide, fluconazole, fluoxetine, fluvastatin, fluvoxamine, isoniazid, lovastatin, ondansetron, phenylbutazone, probenecid, sertraline, sulfamethoxazole, sulfaphenazole, teniposide, voriconazole, warfarin, and zafirlukast
    • Use of cognitive-enhancing supplements such as ginkgo biloba; use of any supplement containing pomegranate or pomegranate juice; use of any investigational drugs within the previous month or longer, depending on drug half-life
    • Pregnancy
Detailed Description: 

Participants will be randomly assigned to take a 1,000-mg pomegranate extract supplement or a placebo every day for 1 year. Their cognitive performance will be tested and compared at the start of the study and after 1, 6, and 12 months. Pomegranate juice is a dietary source of polyphenol antioxidants.

Locations: 
Map Marker CityStateZip CodeStatusPrimary Contact

Geolocation is 34.070264, -118.4440562

Site
Los Angeles
California
90095
Name:
Phone:
Lead Sponsor: 
Agency
University of California, Los Angeles
Collaborator Sponsor: 
Agency
POM Wonderful LLC
Facility Investigators: 
NameAffiliation
Gary Small, MD
University of California, Los Angeles
Study Contact: 
NamePhoneEmail
Jacqueline Martinez
310-206-1319
Locations
 
 
ClinicalTrials.gov ID 
Official Title: 
12-Month, Double-blind, Placebo-Controlled Study of Pomegranate Extract
Study Start Date: 
October 2011
Study End Date: 
January 2015
Disease Stage: 
Pre-clinical
Early
Enrollment: 
212